Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

NCT07137481 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Hematological Malignancies

Interventions

DRUG: C9/CD5CAR/IL-15 NK cells
DRUG: Rituximab
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

M.D. Anderson Cancer Center